We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Evolutec Grp | EVC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 41.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 41.00 | 41.00 |
| Top Posts |
|---|
Posted at 12/4/2007 13:08 by tiborinvest CGT relief?waht a c r a p! not many private investors go above the limit. |
Posted at 08/1/2007 17:01 by frank spencer RNS Number:1635PEvolutec Group PLC 08 January 2007 Evolutec Group plc (the "Company") Holding in Company The Company received notification from Bluehone Investors LLP on 8 January 2007 that, following a purchase of 100,000 ordinary shares of 10 pence each ("Ordinary Shares"), its client Active Capital Trust plc is interested in 1,348,571 Ordinary Shares, representing 5.20% of the Company's issued share capital of 25,949,996 Ordinary Shares. The shares are registered in the name of Chase Nominees Limited. These chaps will be proactive in seeking value for shareholders imo, and given that the company have effectively put themselves up for sale, I suspect we maybe closer to a swift conclusion than is the norm. Those that are unfortunately in at above £1 will likely not see their money back, but I suspect recent buyers are targetting a 30p-50p take out price. |
Posted at 08/1/2007 07:29 by pbracken From the Independent today. Be careful with the author Jivkov, though. His judgements are hoplessly unreliable.Small Talk: Evolutec's stock should get a more favourable treatment By Michael Jivkov Published: 08 January 2007 They say the stock market tends to overshoot both on the upside and the downside. A look at the current valuation of Evolutec certainly proves the second part of that saying. Last week, shares in the biotechnology group slumped after it quite simply admitted that its rEv131 treatment for eye inflammation following cataract surgery does not work. A month earlier, the company had announced that rEV131 is also no good as a remedy for hay fever. So it would seem that Evolutec's compound, which it discovered in proteins found in the saliva of ticks, is of little use to the medical profession. Making things worse for the Reading-based group is the fact that it has few other potential treatments to work on. Given this state of affairs, it is perfectly understandable why investors have been clamouring over one another to exit the stock for some time. But they look to have gone too far. On Friday, Evolutec shares closed at 17p, valuing it at £4.4m. This compares with a cash pile of £8.7m worth 33p a share. Importantly, Mark Brown, the chief executive, has promised that he will not waste any more money on rEV131, which should cut the group's costs dramatically and help to preserve its cash. Mr Brown is now exploring all possible options for the company including its sale or a return of cash to shareholders. Whatever he comes up with, it should result in a significant rise in Evolutec's stock from present levels. |
Posted at 20/12/2006 17:59 by simonparker5 The problem we have got now is all the small T10 investors who are deciding to sell. We still have trial results to be released in January which even if bad can't see this go much lower given the very low current market cap. If they are good or even average then this will go much much higher. Pays your money takes your choice. There still haven't been any large selling over the past three weeks so alot of institutions must still be holding waiting for news. I am happy to sit this one out at then end of the day its only a paper loss, not real until you sell. Good luck everyone. |
Posted at 11/12/2006 15:40 by master rsi RKJONES Some Investors have there feet on the ground, others use their mouth too freely instead of doing research. So you may edit some comments otherwise pay the consecuences |
Posted at 05/12/2006 22:02 by seasons in the sun c_gulli ask again.. provide facts. Is that too hard for such a guru like you ? "The creditors will be payed" - WHAT CREDITORS ?.. do you know how to read financial statements ? ..... then read them and tell me what creditors are you talking about ?... and you are telling me i am 'naive'. " bonuses will be payed" - WHAT BONUSES ? ..... i am sure you have done the research to come out with that sound bite.. so provide the figure. "redundancy payments " - do you know how many employees it has ? a massive 9 employees. All are on rolling contract. 6 of them only joined last year. The total wage bill for ALL 9 is £750k per year. you see I have provided 100% more facts that you have or ever will. Instead of coming out with cliches, provide substantive figures to back up your nonesense, otherwise you will look like a fool, as you are doing now. If you want to 'look' clever at least post provide some factual and relevant data to back up your stance. At the moment its just a bunch of cliches... you may get away with it with less experience investors but not with people who can read through idiots like you who post the usual substanceless garbage. as for me being rude... jeez... you are easily offended. ps its PAID not PAYED. |
Posted at 05/12/2006 20:03 by bubbles11915 26mln shares, assuming £9mln is marginally under 30p per share. Given that this cash sum will diminish, valuing the company at half its cash sum seems a fair base from which to attract value buyers, so a fall to 15p may well be likely.After that,it all depends whether the management have any credibility left with their investors, whom I would have expected them to be in contact with over the last 2 days. By all accounts there was a large placing today representing 15% of the companies shares. In the immediate short-term, its all about demand and supply, and the market will quickly move the shares to a level where there is demand, as there sure seems to be the supply. Perhaps we got there today. I'm going to buy a small amount tomorrow to tuck away. Occasionally, one of these dramatic fallers find their way back, albeit a lot slower than when they fell! There will be no revenue for at least a year, but the talent on the staff, assuming they stay, havn't become ignorant overnight, and the other drugs in the pipeline have a not insignificant chance of success. Certainly not one to put the house on though. |
Posted at 05/12/2006 19:31 by spiv 1 Just thought, this co raised money at 118p in a placing only a month or so ago. They definately would have had an indication then that the clinical trial was not showing efficacy. Companies obviously monitor clinical trials closely. They deliberately kept this quiet to raise cash. I imagine institutions are fuming and its not hard to see why. EVC have well and truly burnt their bridges. Have to say I agree that we will see lower yet. I strongly feel that this sort of deliberate misleading of investors should be prosecuted. I bought the shares based on information released into the public domain, amongst which was the info about the placing. One expects directors to have some integrity, sadly many don't. BTW, I'm not shorting just venting my anger to make myself feel better at losing £3000 plus in a week. |
Posted at 04/12/2006 09:22 by ponderer With Christmas around the corner, I always get excited. Why? Because it's money-making time in the stock markets! It's the time of the year when I can go out and buy presents for friends and family knowing that the markets will pay for everything. I pretty much do the same thing year in year out: buy shares in mid December, and flog them at a profit before January is out.Why? Because even though it's cold outside most years, the December and January markets are hot! The statistics support my argument: the strongest week of the year for the market is the 51st week. And the second strongest? The 52nd week! The third strongest day of the year also falls in December: the 16th, the fourth strongest: December 28th and the fifth: December 23rd.The probability of positive returns in December is a high 69% and the market's only had one significant fall in December since 1981. Both mid and large cap stocks perform equally well. Why are the markets so good at this time of year? I suspect it is down to something as simple as human psychology: the feel good factor as Christmas approaches and the hopes and dreams that comes with the New Year. However, by the end of January we tend to be left with a bit of a hangover and that's why February isn't such a good month. The markets also often fall in October and November as investors begin to come in and buy what they perceive as bargains. So where do I put my money to make the most of the benign conditions? First of all, and I do this every year: I buy the FTSE 100 around December 18th and I sell in early January to take advantage. I usually just make a simple FTSE 100 spreadbet long, with a stop loss in place in case it's the one occasional year when the festive uplift doesn't happen. For example: last year I bought the FTSE at 5495 on December 15th and sold on January 12th at 5735 for an excellent profit of 240 points. I'd placed a £10 a point stake which resulted in a nice profit of £2,400. I also like buying retail stocks in December. These stocks often rise quite a while before (and just after) Christmas in anticipation of high consumer spending. I'm normally out by early January as retailers usually report their Christmas figures in mid January and sometimes the reality isn't so good. Alternatively, the stocks could already have risen in anticipation of good figures so they begin to fall back on profit-taking. I also find that December is a good time to have a look at some of the smaller "tiddler" stocks in the market and have a bit of a gamble. On the downside, one thing to watch out for is companies sneaking out bad news between Christmas and New Year - it's the same as political parties hiding bad news on a big news story day. With so many people away, the companies hope the bad news will go unnoticed so it's worth keeping an eye on news related to your stocks. I tend to get out quick if any kind of bad news is released during the festive period. The period between Christmas and New Year often sees stocks squeezing higher on thin volumes and this year I intend to be at my screen hoping to make some good gains in just a few days. The market is only open for three days during the main festive period this year: December 27th, 28th and 29th. Even though I might well be tucking into mince pies I'm still going to be at my trading desk looking out for opportunities to make some money! Last year many stocks raced higher during the holiday period as often there is simply no-one selling and the institutions are shut. This often has a good effect on stocks at the smaller end of the market. Of course I am making it all sound too easy... this could be the year that it doesn't work out - events could get in my way. But the use of tight stop losses should ensure that if 2006 does not prove to be a bumper Christmas then I won't lose too much after all. I should also point out that markets often don't do what you expect - so what I write here should really come with a warning. I certainly would not buy before Christmas, go away and come back in January. My eyes will continue to monitor the market throughout the festive season. But unless unforeseen political or economic events cause the markets to go through an unseasonable lull, I expect to be buying heavily this Christmas season and hoping the markets will once again pay off that whopping credit card bill, which as usual will land on my doormat in February! |
Posted at 26/11/2006 13:24 by jonfa Here is the Telegraph tip - they have tipped it four times in the last 12 months or so:Take a look at Evolutec (133.5p). The small biotechnology company is developing novel products for the treatment of allergic, inflammatory and auto-immune diseases based on the saliva of tics. Unlike many biotech companies, Evolutec has one proven programme so far rEV131 for hayfever. The market opportunity is large; the World Health Organisation estimates more than 153m people are affected globally. The current mainstay of treatment, steroids, have major drawbacks and sufferers and regulators are looking for an alternative. Evolutec's phase II trial for the product is expected to deliver results before the end of the year. Investors are also expecting further news on clinical results for three new diseases, including inflammation following cataract surgery. Admittedly, our track record with Evolutec is not great. We first advised readers to buy in March 2005 when the shares stood at 175p. But we remain supportive of the company. Investing in biotech is always risky but the allergy market is worth $11bn (£5.7bn) a year and Evolutec is targeting a slice of that. More newsflow should also help underpin the shares. Keep buying. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
